42 active not recruiting, 34 recruiting, 7 not yet recruiting, 4 suspended. 90 Phase 3, 20 Phase 2.
Follow Sample Collection: new trials by email Literature Review of Sample Collection trials Research Report on Sample Collection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2027-03-02 | 2026-10-28 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-28 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-10-27 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer Biospecimen Collection, Carboplatin, Cisplatin - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-12-02 | 2026-10-05 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Biospecimen Collection, Brachytherapy, Carboplatin - Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2025-11-05 | 2026-10-28 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
Showing 20 of 90. Sign in to see all of them.
Lung Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Burkitt Lymphoma (4) · Squamous Cell Carcinoma of Head and Neck (4) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Melanoma (3) · Oropharyngeal Neoplasms (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Renal Cell (2)
National Cancer Institute (NCI) (63) · Children's Oncology Group (15) · NRG Oncology (7) · ECOG-ACRIN Cancer Research Group (3) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (84) · Canada (33) · Puerto Rico (25) · Australia (10) · Israel (4) · New Zealand (4) · Guam (3) · Japan (3) · South Korea (3) · Hong Kong (2) · Saudi Arabia (2) · Switzerland (2) · Germany (1) · Ireland (1) · Netherlands (1)
Aarti Bhatia (1) · Alex F Herrera (1) · Amanda N Fader (1) · Andrea B Apolo (1) · Anwaar Saeed (1) · Bhuvana A Setty (1) · Britt K Erickson (1) · Caitlin W Elgarten (1) · Christine M Bestvina (1) · Christine M Heske (1) · Daniel C Bowers (1) · David A Liebner (1) · David B Zhen (1) · Deborah M Stephens (1)
PMID 37505794, PMID 40966692, PMID 41671463, PMID 41911908, PMID 42335416, PMID 27811504, PMID 29211618, PMID 29784747, PMID 30332335, PMID 30501481, PMID 31449468, PMID 32589970, PMID 32597469, PMID 33152282, PMID 33395032, PMID 33843815, PMID 33878954, PMID 34274940, PMID 34292305, PMID 34340209, PMID 34357781, PMID 34634256, PMID 34686472, PMID 35170751, PMID 35290101, PMID 35304832, PMID 35383907, PMID 35613998, PMID 36006678, PMID 36155490, PMID 36166727, PMID 36416836, PMID 37185961, PMID 38107263, PMID 38215395, PMID 38945791, PMID 38947228, PMID 39047240, PMID 39282902, PMID 39282913, PMID 39413375, PMID 40155326, PMID 40953502, PMID 41137728, PMID 41512237, PMID 41524552, PMID 41529214, PMID 41671459, PMID 41747891, PMID 41880612
U10CA180820 (24), U10CA180868 (17), U10CA180886 (15), U10CA180821 (14), U10CA180888 (13), UG1CA189955 (5), U24CA196173 (4), U24CA196172 (3), U10CA021115 (2), U10CA098543 (2), K23CA178183 (1), R01CA114567 (1), R01CA183444 (1), U01CA246568 (1), U10CA021661 (1)